hotspot -WSS

hotspot

author：knowledge 2025-08-23 08:54:36 - browse：37

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Startling documents reveal new facets of Sacklers' opioid empire

explore

Wikipedia

WSS

Steward Health Care has deal to sell doctor network to UnitedHealth

Prosthetic arm enables patients to feel the objects they grip

Decaf coffee targeted by food safety group under obscure FDA rule

AI used to predict Covid

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Lab trade group sues FDA to halt regulation of lab

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Health insurers say they are turning to AI to cut costs, improve care

New air purifier tech could be key to improving indoor air quality

There's no autism epidemic. It's an autism diagnosis epidemic

Peter Hotez and the public health issue of online harassment

Supreme Court mifepristone arguments center on docs' right to sue

Cancer drug shortages should be causing more outrage

Scientists boost immune system in aging mice by making it youthful

Walensky prepares to leave CDC — and Congress — behind

Childbirth

hotspot

AI used to predict Covid

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Vertex Pharmaceuticals may move headquarters in Boston

Merck drug for rare lung condition set for approval in U.S.

Readout Newsletter: Merck, Vertex, and Viking updates

Adam's Biotech Scorecard: Do Sarepta's exon

explore

Wikipedia

focus

entertainment